Literature DB >> 25499638

Current management of locally advanced head and neck cancer: the combination of chemotherapy with locoregional treatments.

Voichita Bar-Ad1, Joshua Palmer2, Hushan Yang3, David Cognetti4, Joseph Curry4, Adam Luginbuhl4, Madalina Tuluc5, Barbara Campling3, Rita Axelrod3.   

Abstract

This review will discuss the evolution of the role of chemotherapy in the treatment of locally advanced head and neck cancer (HNC), over the last few decades. Studies were identified by searching PubMed electronic databases. Surgery followed by radiotherapy (RT) or definitive RT are potentially curative approaches for locally advanced HNC. While chemotherapy itself is not curative, it can improve cure rates when given as an adjunct to RT. The benefit of combining chemotherapy with RT is related to the timing of the chemotherapy. Several prospective randomized trials have demonstrated that concurrent delivery of chemotherapy and RT (CRT) is the most promising approach, given that locoregional recurrence is the leading pattern of failure for patients with locally advanced HNC. Induction chemotherapy before CRT has not been shown to be superior to CRT alone and the added toxicity may negatively impact the compliance with CRT. Sequential chemotherapy administration, in the form of induction chemotherapy followed by RT or CRT, has been successful as a strategy for organ preservation in patients with potentially resectable laryngeal and hypopharyngeal cancer. Systemic chemotherapy delivered concurrently with RT is used as a standard treatment for locally advanced HNC.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25499638     DOI: 10.1053/j.seminoncol.2014.09.018

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  15 in total

Review 1.  Modulators of Redox Metabolism in Head and Neck Cancer.

Authors:  Xiaofei Chen; Jade Mims; Xiumei Huang; Naveen Singh; Edward Motea; Sarah M Planchon; Muhammad Beg; Allen W Tsang; Mercedes Porosnicu; Melissa L Kemp; David A Boothman; Cristina M Furdui
Journal:  Antioxid Redox Signal       Date:  2017-12-20       Impact factor: 8.401

2.  Prognostic value of the radiomics-based model in progression-free survival of hypopharyngeal cancer treated with chemoradiation.

Authors:  Xiaokai Mo; Xiangjun Wu; Di Dong; Baoliang Guo; Changhong Liang; Xiaoning Luo; Bin Zhang; Lu Zhang; Yuhao Dong; Zhouyang Lian; Jing Liu; Shufang Pei; Wenhui Huang; Fusheng Ouyang; Jie Tian; Shuixing Zhang
Journal:  Eur Radiol       Date:  2019-10-30       Impact factor: 5.315

3.  Discovery of a potent cytotoxic agent that promotes G2/M phase cell cycle arrest and apoptosis in a malignant human pharyngeal squamous carcinoma cell line.

Authors:  Manunya Nuth; Manjunatha R Benakanakere; Robert P Ricciardi
Journal:  Int J Oncol       Date:  2022-02-25       Impact factor: 5.650

4.  Effect of multidrug resistance 1/P-glycoprotein on the hypoxia-induced multidrug resistance of human laryngeal cancer cells.

Authors:  Dawei Li; Liang Zhou; Jiameng Huang; Xiyan Xiao
Journal:  Oncol Lett       Date:  2016-06-17       Impact factor: 2.967

5.  MicroRNA-Target Network Inference and Local Network Enrichment Analysis Identify Two microRNA Clusters with Distinct Functions in Head and Neck Squamous Cell Carcinoma.

Authors:  Steffen Sass; Adriana Pitea; Kristian Unger; Julia Hess; Nikola S Mueller; Fabian J Theis
Journal:  Int J Mol Sci       Date:  2015-12-18       Impact factor: 5.923

6.  Aldehyde dehydrogenase 2*2 knock-in mice show increased reactive oxygen species production in response to cisplatin treatment.

Authors:  Jeewon Kim; Che-Hong Chen; Jieying Yang; Daria Mochly-Rosen
Journal:  J Biomed Sci       Date:  2017-05-22       Impact factor: 8.410

Review 7.  Diagnostic accuracy of magnetic resonance imaging techniques for treatment response evaluation in patients with head and neck tumors, a systematic review and meta-analysis.

Authors:  Anouk van der Hoorn; Peter Jan van Laar; Gea A Holtman; Henriette E Westerlaan
Journal:  PLoS One       Date:  2017-05-24       Impact factor: 3.240

8.  miR-9 modulates and predicts the response to radiotherapy and EGFR inhibition in HNSCC.

Authors:  Francesca Citron; Ilenia Segatto; Lorena Musco; Ilenia Pellarin; Gian Luca Rampioni Vinciguerra; Giovanni Franchin; Giuseppe Fanetti; Francesco Miccichè; Vittorio Giacomarra; Valentina Lupato; Andrea Favero; Isabella Concina; Sanjana Srinivasan; Michele Avanzo; Isabella Castiglioni; Luigi Barzan; Sandro Sulfaro; Gianluigi Petrone; Andrea Viale; Giulio F Draetta; Andrea Vecchione; Barbara Belletti; Gustavo Baldassarre
Journal:  EMBO Mol Med       Date:  2021-06-01       Impact factor: 12.137

9.  Transcriptomic analyses of the radiation response in head and neck squamous cell carcinoma subclones with different radiation sensitivity: time-course gene expression profiles and gene association networks.

Authors:  Agata Michna; Ulrike Schötz; Martin Selmansberger; Horst Zitzelsberger; Kirsten Lauber; Kristian Unger; Julia Hess
Journal:  Radiat Oncol       Date:  2016-07-26       Impact factor: 3.481

10.  Targeting aldehyde dehydrogenase activity in head and neck squamous cell carcinoma with a novel small molecule inhibitor.

Authors:  Jeewon Kim; June Ho Shin; Che-Hong Chen; Leslie Cruz; Lovisa Farnebo; Jieying Yang; Paula Borges; Gugene Kang; Daria Mochly-Rosen; John B Sunwoo
Journal:  Oncotarget       Date:  2017-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.